Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery
Open accessThe DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Breast cancer cell lines have been used widely to investigate breast cancer pathobiology and new therapies. Breast cancer is a molecularly heterogeneous disease, and it is important to understand how well and which cell lines best model that diversity. In particular, microarray studies have identified molecular subtypes-luminal A, luminal B, ERBB2-associated, basal-like and normal-like-with characteristic gene-expression patterns and underlying DNA copy number alterations (CNAs). Here, we studied a collection of breast cancer cell lines to catalog molecular profiles and to assess their relation to breast cancer subtypes. METHODS: Whole-genome DNA microarrays were used to profile gene expression and CNAs in a collection of 52 widely-used breast cancer cell lines, and comparisons were made to existing profiles of primary breast tumors. Hierarchical clustering was used to identify gene-expression subtypes, and Gene Set Enrichment Analysis (GSEA) to discover biological features of those subtypes. Genomic and transcriptional profiles were integrated to discover within high-amplitude CNAs candidate cancer genes with coordinately altered gene copy number and expression. FINDINGS: Transcriptional profiling of breast cancer cell lines identified one luminal and two basal-like (A and B) subtypes. Luminal lines displayed an estrogen receptor (ER) signature and resembled luminal-A/B tumors, basal-A lines were associated with ETS-pathway and BRCA1 signatures and resembled basal-like tumors, and basal-B lines displayed mesenchymal and stem/progenitor-cell characteristics. Compared to tumors, cell lines exhibited similar patterns of CNA, but an overall higher complexity of CNA (genetically simple luminal-A tumors were not represented), and only partial conservation of subtype-specific CNAs. We identified 80 high-level DNA amplifications and 13 multi-copy deletions, and the resident genes with concomitantly altered gene-expression, highlighting known and novel candidate breast cancer genes. CONCLUSIONS: Overall, breast cancer cell lines were genetically more complex than tumors, but retained expression patterns with relevance to the luminal-basal subtype distinction. The compendium of molecular profiles defines cell lines suitable for investigations of subtype-specific pathobiology, cancer stem cell biology, biomarkers and therapies, and provides a resource for discovery of new breast cancer genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Subtype-specific expression and molecular characteristics. (A) Clinical, pathological and molecular characteristics of cell line expression subtypes. Black boxes indicate metastasis derivation, ER-positivity, TP53 mutation, ERBB2/HER2 positivity, PTEN mutation, PIK3CA mutation. Mutation data compiled from the Sanger (http://www.sanger.ac.uk) and IARC (http://www-p53.iarc.fr) websites, and from refs. [94], [95]. White cross-hatched boxes indicate missing data. (B) Classification of cell lines by nearest resemblance to tumor gene-expression subtype: luminal A (dark blue), luminal B (light blue), ERBB2-associated (purple), basal-like (red) or normal-like (green); and by positivity (black boxes) for 70-gene, wound and hypoxia signature. (C) Expression levels of selected stem/progenitor cell relevant markers; log2 ratios are depicted by pseudocolor scale shown (gray represents poorly measured data). (D) Relation of tumor subtypes to cell line subtypes. Subtype of 86 tumors [3] is shown color-coded as above. Resemblance to each cell line subtype is depicted by Euclidian distance, indicated by blue intensity (representing shorter distances); best match is bracketed in black.](https://figures.cochat.ai/paper-figures/dad7ec8c84fc4be4894fefca0af4f9ef/molecular-profiling-of-breast-cancer-cell-lines-defines-relevant-tumor-models-figure-2.jpg)
![Figure 3 Genomic profiles define spectra of CNAs in cell line subtypes. (A) Spectra of gains (red) and losses (green) across the genome, plotted as average log2 ratio, for 89 breast tumors [4], above, compared to the set of 50 cell lines (profiled for both expression and CNAs), below. (B) Spectra of gains and losses for the cell line subtypes: luminal (above), basal A (middle) and basal B (below). Statistically significant subtype-specific CNAs, called by SAM (FDR<5%), are marked by a black bar. The subset of those loci that also characterize the corresponding primary breast tumor subtype is marked by an asterisk.](https://figures.cochat.ai/paper-figures/cc51a551fb5542ec8943fd163510611e/molecular-profiling-of-breast-cancer-cell-lines-defines-relevant-tumor-models-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To effectively distinguish between cell lines from the same donor, it may be necessary to use microarray analysis or next-generation sequencing to perform in depth analysis of gene expression patterns, underlying mutations and copy number alterations.46,47”
From Match criteria for human cell line authentication: Where do we draw the line? (2013) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 2×
“ERBB2 copy number calculation was carried out using the comparative Ct method [8] after validating that the efficiencies of PCR reactions of both ERBB2 and GAST were equal.”
MethodSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 3×
“Hierarchical clustering was used to identify gene-expression subtypes, and Gene Set Enrichment Analysis (GSEA) to discover biological features of those subtypes.”
MethodInfluentialMolecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“To determine the relation between breast cancer cell line subtypes (luminal, basal-A, basal-B) and breast tumor subtypes (luminal-A, luminal-B, ERBB2, basal-like, and normal-like), we first classified cell lines according to tumor subtype using a nearest centroid approach applied to the set of ‘‘intrinsic genes’’ used…”
MethodSelf-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938 · cited 6×
“To determine the relation between breast cancer cell line subtypes (luminal, basal-A, basal-B) and breast tumor subtypes (luminal-A, luminal-B, ERBB2, basal-like, and normal-like), we first classified cell lines according to tumor subtype using a nearest centroid approach applied to the set of ‘‘intrinsic genes’’ used…”
BackgroundMethodResultInfluentialIn silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“Separately, breast cancer stem cells, identified prospectively as tumor initiating cells when transplanted into immunodeficient mice, have been characterized by the surface expression phenotype CD44/CD24 [40], also a presumed phenotype of normal breast epithelial stem or early progenitor cells [84].”
BackgroundGene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429 · cited 2×
“genes with small within-specimen compared to betweenspecimen expression variance), as done previously [15], here using Table 2.”
BackgroundResultHopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 2×
“The set of amplified/overexpressed genes also included many druggable targets [74], most notably several kinases.”
BackgroundA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188 · cited 2×
“[33] profiled 51 breast cancer cell lines (though using a lower-resolution (,1 Mb) CGH platform), 38 of which (,3/4) overlapped with the 52 we profiled.”
ResultSelf-citationNielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Self-citationSotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993 · cited 1×
“While ERBB2 represents a distinct expression tumor subtype in multiple independent cohorts [3,15,81], it is noteworthy that most ERBB2 (HER2+) cell lines clustered in the luminal subtype.”
BackgroundDer, S. D., Zhou, A., Williams, B. R. G., & Silverman, R. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15623 · Cited by 1,816
AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer
Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X.-Y., Sauter, G., Kallioniemi, O.-P., Trent, J. M., & Meltzer, P. S. (1997) · Science · doi:10.1126/science.277.5328.965 · Cited by 1,639
Genome-wide analysis of DNA copy-number changes using cDNA microarrays
Pollack, J. R., Perou, C. M., Alizadeh, A. A., Eisen, M. B., Pergamenschikov, A., Williams, C. F., Jeffrey, S. S., Botstein, D., & Brown, P. O. (1999) · Nature Genetics · doi:10.1038/12640 · Cited by 1,423 · cited 3×
“fluorescence ratios $3, corresponding to at least 5-fold amplification [21]) (Fig.”
BackgroundMethodSelf-citationGenomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,317
Pollack, J. R., Sørlie, T., Perou, C. M., Rees, C. A., Jeffrey, S. S., Lonning, P. E., Tibshirani, R., Botstein, D., Børresen-Dale, A.-L., & Brown, P. O. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162471999 · Cited by 1,167 · cited 1×
“aCGH was performed using cDNA arrays containing 39,632 cDNAs, representing 22,279 mapped human genes (18,049 UniGene clusters [20], together with 4,230 additional mapped ESTs not assigned to UniGene IDs), according to previously published protocols [21,22].”
MethodSelf-citationNibrin, a Novel DNA Double-Strand Break Repair Protein, Is Mutated in Nijmegen Breakage Syndrome
Varon, R., Vissinga, C., Platzer, M., Cerosaletti, K. M., Chrzanowska, K. H., Saar, K., Beckmann, G., Seemanová, E., Cooper, P. R., Nowak, N. J., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81174-5 · Cited by 1,079
Unlocking the potential of the human genome with RNA interference
Hannon, G. J., & Rossi, J. J. (2004) · Nature · doi:10.1038/nature02870 · Cited by 1,064 · cited 1×
“Indeed, high-throughput RNA interference approaches [92,93] might be used to evaluate many or all of the candidate cancer genes simultaneously.”
BackgroundPhenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063 · cited 1×
“The basal-B subtype, which included the three non-tumorigenic lines (consistent with prior studies [75]), as well as five highly invasive/metastatic lines with features of EMT, exhibited enriched expression of EMT and EGF regulated genes, the latter pathway also previously linked to basal-like tumors [79].”
ResultAn integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Chang, H. Y., Sneddon, J. B., Alizadeh, A. A., Sood, R., West, R. B., Montgomery, K., Chi, J.-T., Rijn, M. V. D., Botstein, D., & Brown, P. O. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020007 · Cited by 951 · cited 2×
“We also classified each cell line as being associated with a good or bad prognosis signature (70-gene prognostic signature [17]), the presence or absence of a wound healing signature (512-gene wound signature [18]), and the presence or absence of an hypoxia signature (123-gene hypoxia signature [19]).”
BackgroundVDAC2 Inhibits BAK Activation and Mitochondrial Apoptosis
Cheng, E. H.-Y., Sheiko, T. V., Fisher, J. K., Craigen, W. J., & Korsmeyer, S. J. (2003) · Science · doi:10.1126/science.1083995 · Cited by 852
Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation
Asselin-Labat, M.-L., Sutherland, K. D., Barker, H., Thomas, R., Shackleton, M., Forrest, N. C., Hartley, L., Robb, L., Grosveld, F. G., van der Wees, J., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1530 · Cited by 840 · cited 1×
“The luminal subtype included all ERpositive cell lines, and associated gene expression patterns reflected both ER and luminal differentiation pathways, the latter including GATA3 and FOXA1, key transcriptional mediators of luminal differentiation [28,76].”
BackgroundRelevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update
Lacroix, M., & Leclercq, G. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000014042.54925.cc · Cited by 782 · cited 1×
“Breast cancer cell lines have been used widely to investigate breast cancer pathobiology, and to screen and characterize new therapeutics [6,7].”
BackgroundBreast cancer: origins and evolution
Polyak, K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33295 · Cited by 697
GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland
Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D., & Werb, Z. (2006) · Cell · doi:10.1016/j.cell.2006.09.048 · Cited by 688 · cited 4×
“1H, and not shown) [24–27], as well as genes associated with luminal epithelial differentiation (e.g. GATA3 and FOXA1, Fig.”
BackgroundInfluentialModelling breast cancer: one size does not fit all
Vargo-Gogola, T., & Rosen, J. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2193 · Cited by 679 · cited 1×
“Breast cancer cell lines have been used widely to investigate breast cancer pathobiology, and to screen and characterize new therapeutics [6,7].”
BackgroundMatese, J. C., Sørlie, T., Tibshirani, R., Jeffrey, S. S., Johnsen, H., Brown, P. O., Lønning, P. E., Quist, H., Botstein, D., Eisen, M. B., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/qpxp-y103 · Cited by 679
Wright, M. H., Calcagno, A. M., Salcido, C. D., Carlson, M. D., Ambudkar, S. V., & Varticovski, L. (2008) · Breast Cancer Research · doi:10.1186/bcr1855 · Cited by 642 · cited 1×
“In contrast, basal-A lines appear mainly CD44/CD24, but express PROM1 (aka CD133), a marker of luminal progenitors in mice [86] also more recently characterized as a stem cell marker in BRCA1-associated breast cancer [87], while luminal lines express markers of luminal lineage restriction like GATA3 and FOXA1 [28].”
BackgroundChi, J.-T., Wang, Z., Nuyten, D. S. A., Rodriguez, E. H., Schaner, M. E., Salim, A., Wang, Y., Kristensen, G. B., Helland, Å., Børresen-Dale, A.-L., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030047 · Cited by 619 · cited 2×
“We also classified each cell line as being associated with a good or bad prognosis signature (70-gene prognostic signature [17]), the presence or absence of a wound healing signature (512-gene wound signature [18]), and the presence or absence of an hypoxia signature (123-gene hypoxia signature [19]).”
BackgroundReinhardt, H. C., Aslanian, A. S., Lees, J. A., & Yaffe, M. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.024 · Cited by 596
Gene expression profiling of breast cell lines identifies potential new basal markers
Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adélaïde, J., Cervera, N., Fekairi, S., Xerri, L., Jacquemier, J., Birnbaum, D., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209254 · Cited by 569 · cited 1×
“Cluster analysis of transcriptional profiles defined three cell line subtypes, one luminal and two basal (A and B), consistent with other recent studies of breast cancer cell lines [31,33,75].”
ResultGene expression profiling predicts clinical outcome of breast cancer
(2002) · Nature · doi:10.1038/news020128-6 · Cited by 533
Bergamaschi, A., Kim, Y. H., Wang, P., Sørlie, T., Hernandez‐Boussard, T., Lonning, P. E., Tibshirani, R., Børresen‐Dale, A., & Pollack, J. R. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20366 · Cited by 506 · cited 4×
“Luminal and basal-A lines both exhibited overall higher frequencies of gain/loss (a characteristic feature of basal-like tumors [4]), compared to basal-B lines (Fig.”
BackgroundResultInfluentialSelf-citationCohesin Cleavage by Separase Required for Anaphase and Cytokinesis in Human Cells
Hauf, S., Waizenegger, I. C., & Peters, J.-M. (2001) · Science · doi:10.1126/science.1061376 · Cited by 499 · cited 1×
“Though genes maintaining genome integrity are more typically considered candidate tumor suppressors, the overexpression of such genes has been linked to genome instability [67,89].”
BackgroundBasal-like breast cancer and the BRCA1 phenotype
Turner, N. C., & Reis-Filho, J. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209876 · Cited by 478 · cited 1×
“Consistent with this finding, two breast cancer cell lines from BRCA1 mutation carriers also clustered in basal-A (and basal-A lines exhibited enrichment of a BRCA1 signature), where it has been established that BRCA1associated tumors share many features with sporadic basal-like tumors [80].”
ResultCD44 in Cancer Progression: Adhesion, Migration and Growth Regulation
Marhaba, R., & Zöller, M. (2004) · Journal of Molecular Histology · doi:10.1023/b:hijo.0000032354.94213.69 · Cited by 438
Seals, D. F., Azucena, E. F., Pass, I., Tesfay, L., Gordon, R., Woodrow, M., Resau, J. H., & Courtneidge, S. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.006 · Cited by 384
Pieces of the puzzle: expressed sequence tags and the catalog of human genes
Schuler, G. D. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050155 · Cited by 376 · cited 1×
“aCGH was performed using cDNA arrays containing 39,632 cDNAs, representing 22,279 mapped human genes (18,049 UniGene clusters [20], together with 4,230 additional mapped ESTs not assigned to UniGene IDs), according to previously published protocols [21,22].”
MethodCharacterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue
Stingl, J., Eaves, C. J., Zandieh, I., & Emerman, J. T. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010615124301 · Cited by 367 · cited 1×
“Bipotent human breast epithelial stem/progenitors have been characterized with the cell surface phenotype MUC/CALLA [39].”
BackgroundSaal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355 · cited 1×
“The basal-like cell lines were ER-negative and exhibited more frequent mutations of TP53 and PTEN, consistent with findings in basal-like tumors [3,77].”
ResultSpatial smoothing and hot spot detection for CGH data using the fused lasso
Tibshirani, R., & Wang, P. (2008) · Biostatistics · doi:10.1093/biostatistics/kxm013 · Cited by 347 · cited 1×
“DNA gains and losses were identified using the cghFLasso (R package for Fused Lasso) method [23], which controls the false discovery rate (FDR) by using normal-normal hybridization arrays to approximate the null distribution of the test statistics (see [23] for more details).”
MethodSelf-citationCharacterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.
Tomlinson, G. E., Chen, T. T., Stastny, V., Virmani, A. K., Spillman, M. A., Tonk, V. S., Blum, J. L., Schneider, N. R., Wistuba, I. I., Shay, J. W., et al. (1998) · PubMed · Cited by 345
Self-citationBabu, J. R., Jeganathan, K. B., Baker, D. J., Wu, X., Kang-Decker, N., & van Deursen, J. M. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200211048 · Cited by 339
Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland
Sleeman, K. E., Kendrick, H., Robertson, D., Isacke, C. M., Ashworth, A., & Smalley, M. J. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200604065 · Cited by 321 · cited 1×
“In contrast, basal-A lines appear mainly CD44/CD24, but express PROM1 (aka CD133), a marker of luminal progenitors in mice [86] also more recently characterized as a stem cell marker in BRCA1-associated breast cancer [87], while luminal lines express markers of luminal lineage restriction like GATA3 and FOXA1 [28].”
BackgroundPhosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines
Hollestelle, A., Elstrodt, F., Nagel, J. H. A., Kallemeijn, W. W., & Schutte, M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0263 · Cited by 320
Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening
Silva, J. M., Marran, K., Parker, J. S., Silva, J., Golding, M., Schlabach, M. R., Elledge, S. J., Hannon, G. J., & Chang, K. (2008) · Science · doi:10.1126/science.1149185 · Cited by 318 · cited 1×
“Indeed, high-throughput RNA interference approaches [92,93] might be used to evaluate many or all of the candidate cancer genes simultaneously.”
BackgroundVaillant, F., Asselin-Labat, M.-L., Shackleton, M., Forrest, N. C., Lindeman, G. J., & Visvader, J. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1949 · Cited by 314 · cited 1×
“MUC(2)/CALLA phenotypes characteristic of stem or bipotent progenitor cells, as well as ITGB3 (CD61), also recently characterized as a cancer stem cell marker in MMTV-wnt-1 induced murine breast cancer [41].”
BackgroundTransformation of Different Human Breast Epithelial Cell Types Leads to Distinct Tumor Phenotypes
Ince, T. A., Richardson, A. L., Bell, G. W., Saitoh, M., Godar, S., Karnoub, A. E., Iglehart, J. D., & Weinberg, R. A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.06.013 · Cited by 309 · cited 1×
“[88]) might support the establishment of cell lines from luminal-A tumors.”
BackgroundExpression profiling of epithelial plasticity in tumor progression
Jechlinger, M., Grunert, S., Tamir, I. H., Janda, E., Lüdemann, S., Waerner, T., Seither, P., Weith, A., Beug, H., & Kraut, N. (2003) · Oncogene · doi:10.1038/sj.onc.1206887 · Cited by 294 · cited 4×
“The basal-B subtype, which included the three non-tumorigenic lines (consistent with prior studies [75]), as well as five highly invasive/metastatic lines with features of EMT, exhibited enriched expression of EMT and EGF regulated genes, the latter pathway also previously linked to basal-like tumors [79].”
InfluentialBreast cancer, stem/progenitor cells and the estrogen receptor
Dontu, G., El-Ashry, D., & Wicha, M. S. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.05.011 · Cited by 288 · cited 1×
“basal breast cancer distinction reflects the transformation of different breast epithelial progenitor cell compartments [82,83].”
BackgroundSato, M., Vaughan, M. B., Girard, L., Peyton, M., Lee, W., Shames, D. S., Ramirez, R. D., Sunaga, N., Gazdar, A. F., Shay, J. W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2521 · Cited by 263 · cited 1×
“Preparation of total cell lysates and Western blotting were done as described previously [10].”
MethodSelf-citationCDC6: from DNA replication to cell cycle checkpoints and oncogenesis
Borlado, L. R., & Méndez, J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgm268 · Cited by 262
Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability
Richardson, C., Stark, J. M., Ommundsen, M., & Jasin, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207098 · Cited by 255 · cited 1×
“Though genes maintaining genome integrity are more typically considered candidate tumor suppressors, the overexpression of such genes has been linked to genome instability [67,89].”
BackgroundExpression Profiling of Purified Normal Human Luminal and Myoepithelial Breast Cells
Jones, C., Mackay, A., Grigoriadis, A., Cossu, A., Reis-Filho, J. S., Fulford, L., Dexter, T., Davies, S., Bulmer, K., Ford, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2028 · Cited by 250
Reynolds, J. E., Yang, T., Lü, Q., Jenkinson, J. D., Zhou, P., Eastman, A. R., & Craig, R. W. (1994) · PubMed · Cited by 240
A role for the scaffolding adapter GAB2 in breast cancer
Bentires-Alj, M., Gil, S. G., Chan, R., Wang, Z. C., Wang, Y., Imanaka, N., Harris, L. N., Richardson, A., Neel, B. G., & Gu, H. (2006) · Nature Medicine · doi:10.1038/nm1341 · Cited by 213
Manabe, R.-I., Kovalenko, M., Webb, D. J., & Horwitz, A. R. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.7.1497 · Cited by 204
Origins of breast cancer subtypes and therapeutic implications
Sims, A. H., Howell, A., Howell, S. J., & Clarke, R. B. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0908 · Cited by 198 · cited 1×
“basal breast cancer distinction reflects the transformation of different breast epithelial progenitor cell compartments [82,83].”
BackgroundVolkmer, E., & Karnitz, L. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.567 · Cited by 197
A Secreted Form of ADAM9 Promotes Carcinoma Invasion through Tumor-Stromal Interactions
Mazzocca, A., Coppari, R., De Franco, R., Cho, J.-Y., Libermann, T. A., Pinzani, M., & Toker, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4449 · Cited by 191
Gray, D., Jubb, A. M., Hogue, D., Dowd, P., Kljavin, N., Yi, S., Bai, W., Frantz, G., Zhang, Z., Koeppen, H., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4531 · Cited by 190
Tumour-initiating cells vs. cancer ‘stem’ cells and CD133: What’s in the name?
Neuzil, J., Stantic, M., Zobalova, R., Chladova, J., Wang, X., Prochazka, L., Dong, L., Andera, L., & Ralph, S. J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.159 · Cited by 189 · cited 1×
“Basal-A lines were characterized by expression of PROM1 (aka CD133), a marker of various cancer stem cells [35], as well as other genes like GABRP and VTCN1 (Fig.”
BackgroundMUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Wei, X., Xu, H., & Kufe, D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2005.11.030 · Cited by 186
ETS transcription factors: Possible targets for cancer therapy
Oikawa, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03320.x · Cited by 184 · cited 1×
“The basal-A subtype exhibited enriched expression of ETS pathway genes, a pathway linked to diverse tumor phenotypes including invasion and metastasis [78].”
BackgroundMUC1 alters β-catenin-dependent tumor formation and promotes cellular invasion
Schroeder, J. A., Adriance, M. C., Thompson, M. C., Camenisch, T. D., & Gendler, S. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206291 · Cited by 173
Demeter, J., Beauheim, C., Gollub, J., Hernandez-Boussard, T., Jin, H., Maier, D., Matese, J. C., Nitzberg, M., Wymore, F., Zachariah, Z. K., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1019 · Cited by 172 · cited 2×
“The complete microarray expression data are available at the Stanford Microarray Database (SMD) (http://smd.stanford.edu) and at the Gene Expression Omnibus (GEO) (accession GSE15376); all microarray data reported in the manuscript are described in accordance with MIAME guidelines.”
MethodSelf-citationAdam, L., Vadlamudi, R., Mandal, M., Chernoff, J., & Kumar, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.16.12041 · Cited by 167
Dumont, N., Bakin, A. V., & Arteaga, C. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m204623200 · Cited by 159
Yamamoto, K., Ishiai, M., Matsushita, N., Arakawa, H., Lamerdin, J. E., Buerstedde, J.-M., Tanimoto, M., Harada, M., Thompson, L. H., & Takata, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.15.5421-5430.2003 · Cited by 153
Comparison of features of human breast cancer cell lines and their corresponding tumors.
Wistuba, I. I., Behrens, C., Milchgrub, S., Syed, S., Ahmadian, M., Virmani, A. K., Kurvari, V., Cunningham, T. H., Ashfaq, R., Minna, J. D., et al. (1998) · PubMed · Cited by 147
Self-citationA Comparison of Gene Expression Signatures from Breast Tumors and Breast Tissue Derived Cell Lines
Ross, D. T., & Perou, C. M. (2001) · Disease Markers · doi:10.1155/2001/850531 · Cited by 143 · cited 2×
“The basal-B subtype, which included the three non-tumorigenic lines (consistent with prior studies [75]), as well as five highly invasive/metastatic lines with features of EMT, exhibited enriched expression of EMT and EGF regulated genes, the latter pathway also previously linked to basal-like tumors [79].”
ResultDifferential regulation of human RecQ family helicases in cell transformation and cell cycle
Kawabe, T., Tsuyama, N., Kitao, S., Nishikawa, K., Shimamoto, A., Shiratori, M., Matsumoto, T., Anno, K., Sato, T., Mitsui, Y., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203841 · Cited by 139
Holst‐Hansen, C., Johannessen, B., Høyer‐Hansen, G., Rømer, J., Ellis, V., & Brünner, N. (1996) · Clinical & Experimental Metastasis · doi:10.1007/bf00053903 · Cited by 136 · cited 1×
“Basal-B lines were characterized by markers associated with aggressive tumor features, including PLAT (plasminogen activator) [37] and TGFB1 [38] (Fig.”
BackgroundInterferon-α activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes
Radaeva, S., Jaruga, B., Hong, F., Kim, W., Fan, S., Cai, H., Strom, S. C., Liu, Y., El-Assal, O. N., & Gao, B. (2002) · Gastroenterology · doi:10.1053/gast.2002.32388 · Cited by 135
Hinata, K., Gervin, A. M., Zhang, J. Y., & Khavari, P. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206198 · Cited by 130
Bae, S.-N., Arand, G., Azzam, H. S., Pavasant, P., Torri, J. A., Frandsen, T. L., & Thompson, E. W. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf01833264 · Cited by 123
Boulay, A., Breuleux, M., Stephan, C., Fux, C., Brisken, C., Fiche, M., Wartmann, M., Stumm, M., Lane, H. A., & Hynes, N. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5100 · Cited by 123
Structure of the human oestrogen-responsive gene pS2
Jeltsch, J., Robert, M., Schatz, C., Garnier, J., Brown, A. M., & Chambon, P. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.4.1401 · Cited by 114
Kao, J., & Pollack, J. R. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20339 · Cited by 113
Self-citationLindvall, C. J., Hou, M., Komurasaki, T., Zheng, C., Arsenian‐Henriksson, M., Sedivy, J. M., Björkholm, M., Teh, B. T., Nordenskjöld, M., & Xu, D. (2003) · PubMed · Cited by 106
Cheng, A., Bal, G. S., Kennedy, B. P., & Tremblay, M. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009734200 · Cited by 104
Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells
Inoue, A., Omoto, Y., YAMAGUCHI, Y., Kiyama, R., & Hayashi, S. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0320649 · Cited by 102
Role of Mammalian RAD51L2 (RAD51C) in Recombination and Genetic Stability
French, C. A., Masson, J.-Y., Griffin, C. S., O'Regan, P., West, S. C., & Thacker, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201402200 · Cited by 100
Woodfield, G. W., Horan, A. D., Chen, Y., & Weigel, R. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2293 · Cited by 99
A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling
Draviam, V. M., Stegmeier, F. P., Nalepa, G., Sowa, M. E., Chen, J., Liang, A. C. T., Hannon, G. J., Sorger, P. K., Harper, J. W., & Elledge, S. J. (2007) · Nature Cell Biology · doi:10.1038/ncb1569 · Cited by 97
Botstein, D., Lonning, P. E., Tibshirani, R., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/zsqc-zc97 · Cited by 94
An Oncogenic Role for the Phosphorylated h-Subunit of Human Translation Initiation Factor eIF3
Zhang, L., Smit‐McBride, Z., Pan, X., Rheinhardt, J. M., & Hershey, J. W. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800956200 · Cited by 92
Overexpression of MEKK3 Confers Resistance to Apoptosis through Activation of NFκB
Samanta, A. K., Huang, H. J., Bast, R. C., & Liao, W. S. ‐. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311659200 · Cited by 90
A role for the transcription factor HEY1 in glioblastoma
Hulleman, E., Quarto, M., Vernell, R., Masserdotti, G., Colli, E., Kros, J. M., Levi, D., Gaetani, P., Tunici, P., Finocchiaro, G., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00307.x · Cited by 84
The Valosin-containing Protein (VCP) Is a Target of Akt Signaling Required for Cell Survival
Vandermoere, F., El Yazidi-Belkoura, I., Slomianny, C., Demont, Y., Bidaux, G., Adriaenssens, E., Lemoine, J., & Hondermarck, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510003200 · Cited by 83
Dorsey, J. F., Cunnick, J. M., Mane, S., & Wu, J. (2002) · Blood · doi:10.1182/blood.v99.4.1388 · Cited by 83 · cited 1×
“DORSEY_DOXYCYCLINE_UP Upregulated with GAB2 expression [100] 0.”
Kondo, S., Lu, Y., Debbas, M. E., Lin, A. W., Sarosi, I., Itié, A., Wakeham, A. C., Tuan, J., Saris, C. J. M., Elliott, G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530308100 · Cited by 81
Moesin expression is a marker of basal breast carcinomas
Charafe‐Jauffret, E., Monville, F., Bertucci, F., Esterni, B., Ginestier, C., Finetti, P., Cervera, N., Geneix, J., Hassanein, M., Rabayrol, L., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22923 · Cited by 81
Utilizing prognostic and predictive factors in breast cancer
Subramaniam, D. S., & Isaacs, C. J. (2005) · Current Treatment Options in Oncology · doi:10.1007/s11864-005-0022-1 · Cited by 79 · cited 1×
“Markers such as estrogen receptor (ER), progesterone receptor (PR) and ERBB2/HER2 are used for prognostication, and to stratify patients for appropriately targeted therapies [1].”
BackgroundTari, A. M., Hung, M., Li, K., & Lopez‐Berestein, G. (1999) · Oncogene · doi:10.1038/sj.onc.1202422 · Cited by 74
CAMK1D amplification implicated in epithelial–mesenchymal transition in basal‐like breast cancer
Bergamaschi, A., Kim, Y. H., Kwei, K. A., Choi, Y., Bocanegra, M. C., Langerød, A., Han, W., Noh, D., Huntsman, D. D., Jeffrey, S. S., et al. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.09.004 · Cited by 71 · cited 1×
“Details of the array processing and sample labeling/hybridization methods have been described [12].”
MethodSelf-citationTransforming function of the LSM1 oncogene in human breast cancers with the 8p11–12 amplicon
Streicher, K. L., Yang, Z., Drăghici, S., & Ethier, S. P. (2006) · Oncogene · doi:10.1038/sj.onc.1210002 · Cited by 65
Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer
Molyneux, G., Regan, J. L., & Smalley, M. J. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7391-5 · Cited by 53
Suppression of hypoxic cell death by APIP-induced sustained activation of AKT and ERK1/2
Cho, D.-H., Lee, H.-J., Kim, H.-J., Hong, S.-H., Pyo, J.-O., Cho, C., & Jung, Y.-K. (2006) · Oncogene · doi:10.1038/sj.onc.1210080 · Cited by 46
Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence 2
Qi, C., Zhu, Y. T., Chang, J. S.-M., Yeldandi, A. V., Rao, M. S., & Zhu, Y.-J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.187 · Cited by 40
Zhang, H., Gorn, M., Smith, K., Graham, A., Lau, K. K. W., & Bicknell, R. (1999) · Angiogenesis · doi:10.1023/a:1009085422384 · Cited by 33 · cited 1×
“EGF_HDMEC_UP Upregulated with EGF treatment [99] 0.”
Gudas, J. M., Klein, R. C., Oka, M., & Cowan, K. H. (1995) · PubMed · Cited by 33
Jones, C., Mackay, A. G., Grigoriadis, A. E., Cossu, A., Reis, J., Fulford, L. G., Dexter, T., Davies, S., Bulmer, K., Ford, E., et al. (2003) · UCL Discovery (University College London) · Cited by 30
Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland
Sleeman, K. E., Kendrick, H. D., Robertson, D. M., Isacke, C. M., Ashworth, A., & Smalley, M. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem2041oia1 · Cited by 25
Profiling essential genes in human mammary cells by multiplex RNAi screening
Hannon, G. J., Sj, E., Marran, K., et al. (2021) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/rd3y-vv09 · Cited by 19
Evaluation of oestrogen receptor expression in breast cancer by quantification of mRNA
Potemski, P., Płuciennik, E., Bednarek, A. K., Kusińska, R., Kubiak, R., & Kordek, R. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02886.x · Cited by 17 · cited 1×
“and 59-ACCACGTCGTCCATGTCTTCTTCA-39); ACTB (59 GGCTGTGCTGTGGAAGCTAAG-39 and 59-ATGATGGAGTTGAAGGTAGTTTCGT-39) [9].”
Cited by
Choosing the right cell line for breast cancer research
Holliday, D. L., & Speirs, V. (2011) · Breast Cancer Research · doi:10.1186/bcr2889 · Cited by 1,541
“In general, these studies have shown that the luminal, basal, HER2 and claudin-low clusters identifi ed in breast tumours can easily be distinguished in breast cancer cell lines (Table 1) [13,22-26].”
ResultBreast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping
Dai, X., Cheng, H., Bai, Z., & Li, J. (2017) · Journal of Cancer · doi:10.7150/jca.18457 · Cited by 1,100
“MDAMB361 + +/- + WT LB MDA RPMI, DMEM AC L [1, 5, 6, 8, 10]”
BackgroundMethodInfluentialDeRose, Y. S., Wang, G., Lin, Y.-C., Bernard, P. S., Buys, S. S., Ebbert, M. T. W., Factor, R., Matsen, C., Milash, B. A., Nelson, E., et al. (2011) · Nature Medicine · doi:10.1038/nm.2454 · Cited by 1,002
“This work revealed that (1) our current bank of tumor grafts, which is still growing, already comprises all major clinical types of breast cancer, and multiple molecular subtypes; (2) tumor grafts maintain critical features of the patient tumors including histology and pathology, clinical markers, gene expression prof…”
BackgroundWeigman, V. J., Chao, H.-H., Shabalin, A. A., He, X., Parker, J. S., Nordgard, S. H., Grushko, T., Huo, D., Nwachukwu, C., Nobel, A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1846-y · Cited by 902
“In addition, human Claudin-low cell lines, which are often called ‘‘Basal B’’ lines, also have a similar flat copy number profile of showing very few chromosomal abnormalities [20].”
BackgroundExosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
Boelens, M. C., Wu, T. J., Nabet, B. Y., Xu, B., Qiu, Y., Yoon, T., Azzam, D. J., Twyman-Saint Victor, C., Wiemann, B. Z., Ishwaran, H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.051 · Cited by 806
Metadata
- Authors
- Kao, J., Salari, K., Bocanegra, M., Choi, Y.-L., Girard, L., Gandhi, J., Kwei, K. A., Hernandez-Boussard, T., Wang, P., Gazdar, A. F., Minna, J. D., & Pollack, J. R.
- Affiliations
- Stanford Medicine (US)
- Stanford University (US)
- Samsung Medical Center (KR)
- The University of Texas Southwestern Medical Center (US)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Pollack, Jonathan R.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-07-03
- Volume
- 4
- Issue
- 7
- Pages
- e6146
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2702084
- OpenAlex
- W2066122607
- Cited by
- 788
- References
- 108
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 33 · 2023: 33 · 2022: 28 · 2021: 56 · 2020: 49 · 2019: 40 · 2018: 43 · 2017: 60 · 2016: 65 · 2015: 68 · 2014: 93 · 2013: 77 · 2012: 55
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- California Breast Cancer Research Program
- National Institutes of Health
- National Cancer Institute (T32CA009151, CA 97139, R01CA097139, T32CA009302)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- breast cancer cell lines, molecular subtypes, luminal A, luminal B, basal-like breast cancer, DNA copy number alterations, gene expression profiling, candidate cancer genes, cancer stem cells, mesenchymal phenotype
- MeSH terms
- Base Sequence, Breast Neoplasms, Female, Humans, Immunohistochemistry, RNA, Messenger, Transcription, Genetic, Blotting, Western, Polymerase Chain Reaction, DNA Primers, Genes, BRCA1, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.